Research Analysts Set Expectations for VIGL FY2026 Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Vigil Neuroscience in a research report issued on Tuesday, May 27th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.84) for the year, down from their prior estimate of ($0.64). HC Wainwright has a "Neutral" rating and a $8.00 price objective on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. HC Wainwright also issued estimates for Vigil Neuroscience's FY2027 earnings at ($0.15) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $0.63 EPS.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04.

Other research analysts have also issued research reports about the company. Citizens Jmp lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Guggenheim set a $8.00 price target on Vigil Neuroscience and gave the stock a "neutral" rating in a report on Thursday, May 22nd. Citigroup lowered shares of Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Mizuho lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Finally, Wedbush lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $13.00 to $8.00 in a report on Thursday, May 22nd. Ten investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL remained flat at $7.88 during trading on Thursday. The stock had a trading volume of 1,210,695 shares, compared to its average volume of 657,423. Vigil Neuroscience has a fifty-two week low of $1.31 and a fifty-two week high of $7.95. The company's 50-day moving average is $2.79 and its two-hundred day moving average is $2.45. The stock has a market cap of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90.

Hedge Funds Weigh In On Vigil Neuroscience

Institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC boosted its holdings in Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after purchasing an additional 8,358 shares in the last quarter. Northern Trust Corp boosted its holdings in Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares in the last quarter. Barclays PLC boosted its holdings in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares in the last quarter. Two Sigma Investments LP boosted its holdings in Vigil Neuroscience by 44.0% in the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company's stock valued at $233,000 after purchasing an additional 41,836 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Vigil Neuroscience in the fourth quarter valued at approximately $83,000. 83.64% of the stock is owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.